FA
UTHR icon

Fiduciary Alliance’s United Therapeutics UTHR Stock Holding History

Fiduciary Alliance’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51M Buy
8,324
+1,638
+24% +$922K 0.3% 86
2026
Q1 		$3.86M Buy
6,686
+6,082
+1,007% +$3.03M 0.23% 108
2025
Q4 		$294K Buy
+604
New +$281K 0.02% 421

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Fiduciary Alliance's UTHR Position: Q2 2026 in Review

Fiduciary Alliance increased its United Therapeutics (UTHR) stake by 24% in Q2 2026, buying an estimated $922K and bringing the position to 8,324 shares worth $4.51M. The position accounts for 0.3% of the portfolio, ranked #86.

Fiduciary Alliance first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Fiduciary Alliance held 8,324 shares of United Therapeutics worth $4.51M as of Q2 2026.
  • Fiduciary Alliance bought 1,638 United Therapeutics shares in Q2 2026, an estimated $922K.
  • United Therapeutics made up 0.3% of Fiduciary Alliance's portfolio in Q2 2026, its #86 holding.
  • Fiduciary Alliance first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Fiduciary Alliance's 13F filing for Q2 2026, filed 20 Jul 2026.